Search results
Profile. I am a haematology specialist registrar currently pursuing an MD (res) at the National Amyloidosis Centre. I graduated from University College London in 2011 and have done all my training in North/Central London. I have a special interest in plasma cell dyscrasias such as AL amyloidosis and multiple myeloma.
- Dr Katherine Cwynarski
Patient reviews of Dr Katherine Cwynarski - Page . Brilliant...
- Dr Farrukh Shah
Words cannot do justice in how Dr Shah has taken care of me...
- Dr Katherine Cwynarski
Mandy Krauthamer Cohen (born September 17, 1978) [ 1 ] is an American internist, public health official, and healthcare executive serving as the director of the U.S. Centers for Disease Control and Prevention (CDC) since July 10, 2023.
Oliver Mansour Jackson-Cohen (born 24 October 1986) is a British actor and model. He is best known for his role as Adrian Griffin in the 2020 adaptation of The Invisible Man and for his roles as Luke Crain and Peter Quint in the Netflix television programmes The Haunting of Hill House (2018) and The Haunting of Bly Manor (2020) respectively.
He is best known for his role as Adrian Griffin in the 2020 adaptation of The Invisible Man and for his roles as Luke Crain and Peter Quint in the Netflix television programs The Haunting of Hill House (2018) and The Haunting of Bly Manor (2020) respectively.
- January 1, 1
- 1.91 m
- Westminster, London, England, UK
Oliver C Cohen's 41 research works with 414 citations and 1,768 reads, including: P910: DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS...
May 5, 2021 · In this randomized clinical trial that included 370 adults with moderate to severe traumatic brain injury, treatment with continuous infusion of 20% hypertonic saline vs standard care resulted in an odds ratio for better neurological outcomes (based on the Extended Glasgow Outcome Scale) of 1.02 after 6 months; this was not statistically signifi...
May 9, 2024 · Event rates were overestimated in 61.1% of trials, with the proportion of trials overestimating effect sizes coming in at 82.1%, researchers led by Christoph Olivier, MD (University Heart Center Freiburg-Bad Krozingen, Germany), report in a study published online recently in JAMA Network Open.
